BMS/Pfizer's Eliquis better than Sanofi's Lovenox for hip but not knee, IQWiG says
This article was originally published in Scrip
Executive Summary
Pfizer/Bristol-Myers Squibb's anticoagulant Eliquis (apixaban) is slightly better than the low-molecular weight heparin enoxaparin (Sanofi's Lovenox)at preventing symptomatic venous thromboembolism after hip replacement, but is less beneficial than the comparator following knee replacement surgery, says IQWiG, Germany's Institute for Quality and Efficiency.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.